Allogene Therapeutics, Inc.

Hello, and thank you for standing by. Welcome to the Allergen Therapeutics third quarter 2023 conference call. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. You will then hear an automated message advising you that your hand is raised. To withdraw your question, please press star 1-1 again. Please be aware that today's conference is being recorded. I would now like to turn the call over to Christine Cassiano, Chief Corporate Affairs and Brand Strategy Officer. Ms. Cassiano, please go ahead.

Thank you, Operator, and welcome to our call. Today, after market closed, Allogene issued a press release that provides a business update and financial results for the third quarter of 2023. This press release and today's webcast are both available on our website. Following our prepared remarks, we will host a Q&A session. We ask you to limit your questions to one per person as we will keep this call to an hour and do our best to get to as many questions as possible. Joining me today are Dr. David Chang, President and Chief Executive Officer, Dr. Zachary Roberts, Executive Vice President of Research and Development and Chief Medical Officer, and Jeff Parker, Chief Financial Officer. During today's call, we will be making certain forward-looking statements. These may include statements regarding the success and timing of our ongoing and planned clinical trials data presentations, regulatory filings, future research and development efforts, manufacturing capabilities, the safety and efficacy of our product candidates, and 2023 financial guidance, among other things. These forward-looking statements are based on current information, assumptions, and expectations that are subject to change. A description of potential risks can be found in our earnings press release and the latest SEC disclosure documents. You're cautioned not to place undue reliance on these forward-looking statements, and Allogene disclaims any obligation to update these statements. I'll now turn the call over to David.

Thank you, Christine, and welcome to all listening to our call today. The last few weeks have been exciting in the field of cell therapy. from an uptake in autologous CAR T cells and the release of abstract this morning for the upcoming American Society of Hematology meeting to witnessing the potential of CAR T therapy beyond oncology. It is clear that we are just at the beginning of what's possible for patients with this modality. While indications outside of oncology have been the focus of the field as of late, something we are keeping a keen eye on, I will focus our call today on CAR T in oncology. Throughout the decades, cancer therapies have come in great waves. Cytotoxic chemotherapy was the first wave, spending most of the 20th century as fundamental discoveries in blood cancers gave way to increasingly sophisticated combination therapies that could be used against all tumors. The second wave was monoclonal antibodies, a scientific breakthrough that even today continues to fuel innovation with follow-on technology platforms. I would argue that this wave also includes antibody-drought conjugates by specific antibodies and by specific T cell engagers. The third wave has been a more gradual emergence of targeted therapies in today's omics era. Pathways that govern the behavior of our cells have been delineated, paving a way to precisely enter the disease. We are now at the beginning of a fourth great wave. The era of engineered cell therapy. The enablement of synthetic biology to harness the power of immune cells is now peaceful through the convergence of knowledge of cellular pathways and technological breakthroughs in gene editing and cell engineering. But this fourth-grade wave can only be fully unlocked when industry makes CAR-P accessible to all eligible patients. This was an important topic during recent discussions at both the future summit hosted by STEP as well as at the American Society for Transplantation and Cellular Therapy-Sponsored Accelerate Forum on a panel moderated by Dr. Peter Marks, Director of Center for Biologic Evaluation and Research, and Dr. Marcello Paschini of the Center for International Blood and Narrow Transplant Research. At AlloGene, we believe that the key to unlocking this potential is AlloGene card key, and if you will, creating the Konami code for cell therapy. For those who know video games, the Konami code was originally a simple sequence of buttons that would give a full set of power-ups to make testing easier for developers. The modern-day concept of this code is no longer just about making a game easier. Rather, it is now unlocking hidden expert modes, enabling expansion of the game. And that is exactly how we are thinking about our platform. It is creating the Konami code for allogeneics authorities. Of course, they can be applied not just in the industry's first potentially pivotal trial of an allogeneic CAR T product, but in other harder modes, such as early-aligned trials, solid tumors, non-oncology indications, and next-generation products. And we look forward to the month ahead where certain scientific aspects of this code will come to life, unlocking new opportunities and broadening patient access to the fourth-grade way. Before I turn the call over to Zach to give a brief overview of what will be presented at the Society for Immunotherapy of Cancer and what's expected at ASH. I would also like to take the opportunity to officially welcome the newest member of our leadership team to his first Allogene quarterly call, Jeff Parker. In this especially challenging market, Jeff's extensive experience in biotechnology across all aspects of finance and business development strategy will be of tremendous value to Allogene as we advance our critical pipeline assets and explore new opportunities. I am confident He will be instrumental to our success as we navigate the next chapter. I would now like to turn the call over to Zach.